SG Americas Securities LLC Has $1.89 Million Holdings in Intersect ENT Inc (XENT)

SG Americas Securities LLC lowered its position in Intersect ENT Inc (NASDAQ:XENT) by 55.2% in the first quarter, HoldingsChannel.com reports. The fund owned 58,825 shares of the medical equipment provider’s stock after selling 72,379 shares during the quarter. SG Americas Securities LLC’s holdings in Intersect ENT were worth $1,891,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the business. Squarepoint Ops LLC raised its position in shares of Intersect ENT by 1.2% in the fourth quarter. Squarepoint Ops LLC now owns 46,588 shares of the medical equipment provider’s stock worth $1,313,000 after acquiring an additional 547 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Intersect ENT by 0.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 162,078 shares of the medical equipment provider’s stock worth $4,567,000 after acquiring an additional 609 shares during the period. NumerixS Investment Technologies Inc raised its position in shares of Intersect ENT by 43.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 2,200 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 662 shares during the period. Legal & General Group Plc raised its position in shares of Intersect ENT by 14.8% in the fourth quarter. Legal & General Group Plc now owns 5,353 shares of the medical equipment provider’s stock worth $151,000 after acquiring an additional 690 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Intersect ENT by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 15,945 shares of the medical equipment provider’s stock worth $449,000 after acquiring an additional 739 shares during the period. Institutional investors and hedge funds own 95.98% of the company’s stock.

In other news, CFO Jeryl L. Hilleman sold 30,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $32.07, for a total value of $962,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David Aaron Lehman sold 9,000 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $33.04, for a total transaction of $297,360.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 106,246 shares of company stock valued at $3,269,037. 5.90% of the stock is owned by insiders.

XENT stock opened at $27.73 on Friday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -36.49 and a beta of 0.62. Intersect ENT Inc has a 12 month low of $24.39 and a 12 month high of $42.95.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Monday, May 6th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.05). The business had revenue of $26.70 million during the quarter, compared to analyst estimates of $26.34 million. Intersect ENT had a negative net margin of 21.13% and a negative return on equity of 19.04%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.21) EPS. Equities research analysts expect that Intersect ENT Inc will post -1.07 earnings per share for the current year.

A number of brokerages have weighed in on XENT. BidaskClub upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a research report on Friday, May 3rd. Svb Leerink downgraded shares of Intersect ENT from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $29.00 in a research report on Tuesday. Northland Securities downgraded shares of Intersect ENT from a “market perform” rating to an “under perform” rating and reduced their price target for the stock from $28.00 to $20.00 in a research report on Tuesday. Finally, ValuEngine upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $30.96.

TRADEMARK VIOLATION NOTICE: “SG Americas Securities LLC Has $1.89 Million Holdings in Intersect ENT Inc (XENT)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/10/sg-americas-securities-llc-has-1-89-million-holdings-in-intersect-ent-inc-xent.html.

Intersect ENT Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: What Does a Sell-Side Analyst Rating Mean?

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.